Pharmaceutical composition and method of preparing same
AssigneesThe University of Tokushima, Saisei Mirai Clinic
InventorsYoshihiro UTO, Hitoshi HORI, Toshio INUI, Kentaro KUBO
Life of this patent
Estimating the term…
Abstract
An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with β-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.
Claims4
A method of treating a human suffering from cancer, HIV or AIDS, consisting essentially of:
- administering a therapeutically effective amount of a pharmaceutical composition consisting essentially of a beta-galactosidase and sialidase treated human serum to the human suffering from cancer, HIV or AIDS,
- said composition being prepared by bringing a human serum from blood of a patient suffering from cancer, HIV or AIDS into contact with beta-galactosidase and sialidase to yield the pharmaceutical composition, and
- said pharmaceutical composition being administered to the patient.
A method of treating a human suffering from cancer, consisting essentially of:
- administering a therapeutically effective amount of a pharmaceutical composition consisting essentially of a beta-galactosidase and sialidase treated human serum to the human suffering from cancer,
- said composition being prepared by bringing a human serum from blood of a healthy human into contact with beta-galactosidase and sialidase to yield the pharmaceutical composition;
- wherein the pharmaceutical composition consists essentially of proteins in an amount of 0.1 mg/kg to 2.0 mg/kg per dose.
A method of treating a human suffering from HIV or AIDS, consisting essentially of:
- administering a therapeutically effective amount of a pharmaceutical composition consisting essentially of a beta-galactosidase and sialidase treated human serum to the human suffering from HIV or AIDS,
- said composition being prepared by bringing a human serum from blood of a healthy human into contact with beta-galactosidase and sialidase to yield the pharmaceutical composition;
- wherein the pharmaceutical composition consists essentially of proteins in an amount of 0.1 mg/kg to 2.0 mg/kg per dose.
Dependencies are inferred from the claim text.